Totally Implantable Venous Access Devices

Management in Mid- and Long-term Clinical Setting

  • Authors
  • John E. Niederhuber
  • Isidoro Di Carlo
  • Roberto Biffi

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Introduction

    1. Front Matter
      Pages 1-1
    2. Roberto Biffi
      Pages 3-9
    3. Jason Malenfant, Kathleen Bubb, Alena Wade, R. Shane Tubbs, Marios Loukas
      Pages 11-17
  3. Totally Implantable Access Devices

    1. Front Matter
      Pages 35-35
    2. Isidoro Di Carlo, Adriana Toro
      Pages 43-54
    3. Philip Knebel, Roland Hennes, Markus K. Diener, Christoph M. Seiler, Markus W. Büchler
      Pages 71-78
  4. Immediate Complication: Prevention and Treatment

    1. Front Matter
      Pages 105-105
    2. Roberto Biffi
      Pages 107-113
    3. Hasan Karanlik, Sidika Kurul
      Pages 115-121
    4. Hasan Karanlik, Sidika Kurul
      Pages 123-128
    5. Zhang Qinming
      Pages 129-131
    6. Adriana Toro, Isidoro Di Carlo
      Pages 133-136
    7. Adriana Toro, Isidoro Di Carlo
      Pages 137-140

About this book

Introduction

Since their first application in 1982, Totally Implantable Venous Access Devices (TIVADs) have become increasingly important in the clinical practice, as more intensive chemotherapy and parenteral treatments have come into use. At this time, there is objective evidence that TIVADs are a safe, effective strategy for long-term venous access; they play a significant role throughout the management of the oncology patient, as they are needed in the initial phases for active treatments as well as in the last stages for palliative measures, making possible repeated administration of chemotherapeutic vesicant agents, nutrients, antibiotics, analgesics, and blood products. According to a number of prospective studies, use of TIVADs is associated with a significant complication rate (10% to 25% of all patients). Evidence-based data support that most complications are directly related to inappropriate technique of placement and/or nursing care, sometimes leading to TIVAD loss, significant morbidity, increased duration of hospitalization, and additional medical cost.

A group of world-renowned experts - both in the clinical and research fields – contributed to this volume, whose aim is to provide clinicians, nurses and medical students with a multidisciplinary, full update on these devices, as long term central venous access can no be longer considered a routine matter, and serious complications can be maintained at a very low level only if strict adherence to a well-defined protocol of surgical technique and of catheter care is maintained.

Keywords

central venous access devices chemioterapy port surgical cut-down totally implantable venous access device

Editors and affiliations

  • Isidoro Di Carlo
    • 1
  • Roberto Biffi
    • 2
  1. 1.Department of Surgical Sciences Organ Transplantation and Advanced TechnologiesUniversity of Catania Cannizzaro HospitalCataniaItaly
  2. 2.Division of Abdomino Pelvic SurgeryEuropean Institute of OncologyMilanItaly

Bibliographic information

  • DOI https://doi.org/10.1007/978-88-470-2373-4
  • Copyright Information Springer-Verlag Italia 2012
  • Publisher Name Springer, Milano
  • eBook Packages Medicine
  • Print ISBN 978-88-470-2372-7
  • Online ISBN 978-88-470-2373-4
  • About this book
Industry Sectors
Biotechnology
Pharma